Ulrica Slåne Bjerke
Amministratore Delegato presso Arctic Asset Management AS (Sweden)
Provenienza dei contatti di primo grado di Ulrica Slåne Bjerke
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Public Company | Financial Conglomerates | 20 | |
4
| Public Company | Industrial Machinery | 4 |
Arctic Asset Management AS (Sweden)
 Arctic Asset Management AS (Sweden) Investment ManagersFinance Arctic Asset Management AS (Sweden) (AAM-Sweden) is the Sweden-based investment management arm of Arctic Asset Management AS, ultimately owned by Arctic Securities AS in Norway. The firm was founded in 2016 and is headquartered in Stockholm. AFM-Sweden manages portfolio of Nordic equities, Nordic fixed income and Global Life Science – through mutual funds and discretionary mandates for institutional clients, family offices, investment companies and private clients.
3
| Operating Division | Investment Managers | 3 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Ulrica Slåne Bjerke tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
Karolinska Development AB (Private Equity)
 Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | Investment Managers | Private Equity Investor Chief Executive Officer Private Equity Investor Chief Executive Officer Private Equity Investor Private Equity Investor Private Equity Analyst | |
| KCIF Fund Management AB | Director/Board Member Chief Executive Officer Chief Executive Officer Chairman Chief Executive Officer | ||
Athera Biotechnologies AB
 Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Director of Finance/CFO | |
Palette Life Sciences AB
 Palette Life Sciences AB Medical SpecialtiesHealth Technology Palette Life Sciences AB operates as a pharmaceutical company. It specializes in developing products for local pain relief in obstetrics and gynecology. The company was founded by Berith Karlsson Tingåker, Gunvor Ekman-Ordeberg, Arne Folke Brodin and Lars Irestedt in 2009 and is headquartered in Solna, Sweden. | Medical Specialties | Director/Board Member Director/Board Member Director/Board Member Director of Finance/CFO | |
KDev Exploratory AB
 KDev Exploratory AB Miscellaneous Commercial ServicesCommercial Services KDev Exploratory AB provides drug discovery solutions. It performs discovery research in various therapeutic areas, such as screening in oncology, neuroscience, lead finding, characterization in inflammation and angiogenesis/age-related macular degeneration. The company was founded by David Jern in 2000 and is headquartered in Solna, Sweden. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Chief Administrative Officer Chief Executive Officer | |
| Royal Institute of Technology | College/University | Corporate Officer/Principal Graduate Degree Graduate Degree Graduate Degree | |
| Karolinska Institutet | College/University | Corporate Officer/Principal Doctorate Degree Doctorate Degree | |
| SYNACT PHARMA AB | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Director/Board Member | |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
NovaSAID AB
 NovaSAID AB Pharmaceuticals: MajorHealth Technology NovaSAID AB develops treatments for inflammation and pain in conditions such as rheumatoid arthritis. It discovers selective microsomal prostaglandin E synthase-1 (mPGES-1), and has also demonstrated its effect in animal models for pain and inflammation. The firm's approach is to prevent the pathological formation of prostaglandin E2 (PGE2) selectively, through the development of inhibitors of mPGES-1, the enzyme that is responsible for the formation of PGE2 during inflammation. Its mPGES-1 inhibition offers an approach for inhibiting pathological PGE2 production without adversely affecting other important prostanoids. The company was founded by Per-Johan Göte Jakobsson, Ralf Morgenstern, Bertil Samuelsson and Bengt Ingemar Samuelsson on October 26, 2004 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chairman Comptroller/Controller/Auditor Chairman | |
| ASARINA PHARMA AB | Pharmaceuticals: Major | Chairman Public Communications Contact Comptroller/Controller/Auditor | |
| OREXO AB | Pharmaceuticals: Major | Chief Executive Officer Chief Tech/Sci/R&D Officer Director/Board Member | |
Akinion Pharmaceuticals AB
 Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Corporate Officer/Principal | |
| MEDIVIR AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Tech/Sci/R&D Officer | |
ClanoTech AB
 ClanoTech AB Pharmaceuticals: MajorHealth Technology ClanoTech AB is a holding company that develops drugs for the treatment of cancer and macular degeneration. Its lead candidate is an inhibitor of the alpha5beta1-integrin receptor which is present in fibroblast and on vascular endothelial cells. Its Alpha5beta1-integrin is strongly up-regulated in fibroblast when switching to the fibrotic state and in scars after glaucoma surgery. Its strategy spans from therapeutic areas with high commercial potential as wet Age Regulated Macular Degeneration to ophthalmology niche indications with orphan drug opportunity such as developing advent in glaucoma surgery techniques. The company was founded by Yihai Cao in 2006 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
| KD Incentive AB | Director/Board Member Director/Board Member Director/Board Member | ||
Dilafor AB
 Dilafor AB Pharmaceuticals: MajorHealth Technology Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Founder Director of Finance/CFO | |
| INHALATION SCIENCES SWEDEN AB | Medical Specialties | Director of Finance/CFO Director of Finance/CFO | |
| ONCOZENGE AB | Pharmaceuticals: Major | Chief Executive Officer Director of Finance/CFO | |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
Biosergen AS
 Biosergen AS BiotechnologyHealth Technology Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway. | Biotechnology | Director/Board Member Director/Board Member | |
| LIPIDOR AB | Miscellaneous Commercial Services | Director/Board Member Director of Finance/CFO | |
| NEOS AB | Medical Specialties | Chairman Director/Board Member | |
| MODUS THERAPEUTICS HOLDING AB | Biotechnology | Director/Board Member Director/Board Member | |
Biolipox AB
 Biolipox AB Pharmaceuticals: MajorHealth Technology Biolipox AB develops and manufactures pharmaceuticals products. The company engages in the research and development of pharmaceuticals for the treatment of respiratory and other inflammatory diseases such as asthma, chronic obstructive pulmonary disease, rhinitis, pain, and arthritis. It was founded in June 2000 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chief Executive Officer Chief Tech/Sci/R&D Officer | |
| ONCOPEPTIDES AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
KDev Oncology AB
 KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | Miscellaneous Commercial Services | Chief Executive Officer Chairman | |
| ZICCUM AB | Medical Specialties | Corporate Officer/Principal Director of Finance/CFO | |
| CALLIDITAS THERAPEUTICS AB | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| PROMIMIC AB | Medical Specialties | Director/Board Member | |
| MEDA AB | Pharmaceuticals: Major | Chairman | |
| XSPRAY PHARMA AB | Pharmaceuticals: Major | Director/Board Member | |
| Venture Cup Ost | Director/Board Member | ||
Umecrine AB
 Umecrine AB BiotechnologyHealth Technology Umecrine AB provides pharmaceuticals against mental and physical symptoms. It develops antagonists to reduce symptoms and conditions caused by endogenous sex and stress hormones on the brain. The company was founded by Carl Torbjörn Bäckström in 2000 and is headquartered in Umea, Sweden. | Biotechnology | Chairman | |
| OSSDSIGN AB | Medical Specialties | Director/Board Member | |
Biochromix AB
 Biochromix AB Medical SpecialtiesHealth Technology BioChromix AB manufactures diagnostic products. It is a company in the life science arena that develops and commercializes products for early stage diagnostics of Alzheimer's disease (AD) and identification of biomarkers associated to AD. The firm’s methods are based on their novel and patented Luminescent Conjugated Polymer (LCP) molecules. The company is headquartered in Solna, Sweden. | Medical Specialties | Director/Board Member | |
Umecrine Cognition AB
 Umecrine Cognition AB Pharmaceuticals: MajorHealth Technology Umecrine Cognition AB develops pharmaceuticals against neurological disorders in the central nervous system. The firm focuses on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. The company was founded by Torbjörn Bäckström in 2006 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
| Stockholm Biotechbuilders Association | Director/Board Member | ||
AB Wilhelm Becker
 AB Wilhelm Becker Chemicals: SpecialtyProcess Industries AB Wilhelm Becker operates as a holding company with interests in chemical companies. It manufactures industrial coatings for metals and plastics, and products for surface treatment of wood. The company is headquartered in Hoganas, Sweden. | Chemicals: Specialty | Corporate Officer/Principal | |
| Kabi Pharmacia | Corporate Officer/Principal | ||
| Pharmor AB | Chief Executive Officer | ||
| NANEXA AB | Medical Specialties | Corporate Officer/Principal | |
| Isles of Wines AB | Chief Executive Officer |
Statistiche
Distribuzione geografica
| Svezia | 49 |
| Norvegia | 2 |
| Danimarca | 2 |
Settori
| Health Technology | 33 |
| Commercial Services | 8 |
| Consumer Services | 3 |
| Finance | 2 |
| Process Industries | 2 |
Posizioni
| Director/Board Member | 179 |
| Corporate Officer/Principal | 67 |
| Chairman | 50 |
| Independent Dir/Board Member | 29 |
| Chief Executive Officer | 28 |
Contatti più connessi
- Borsa valori
- Insiders
- Ulrica Slåne Bjerke
- Connessioni Società
